Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

被引：0

作者：

Goergen, Ellinor ^{[1
,2
]}

von Tresckow, Julia ^{[3
]}

Giza, Adam ^{[1
,2
]}

Robrecht, Sandra ^{[1
,2
]}

Fink, Anna-Maria ^{[1
,2
]}

Fischer, Kirsten ^{[1
,2
]}

Al-Sawaf, Othman ^{[1
,2
]}

Fuerstenau, Moritz ^{[1
,2
]}

Simon, Florian ^{[1
,2
]}

Kutsch, Nadine ^{[1
,2
]}

Nieper, Pascal ^{[1
,2
]}

Tausch, Eugen ^{[4
]}

Ritgen, Matthias ^{[5
]}

Boettcher, Sebastian

Kreuzer, Karl-Anton ^{[1
,2
]}

Stilgenbauer, Stephan ^{[4
,6
]}

Langerbeins, Petra ^{[1
,2
]}

Eichhorst, Barbara ^{[1
,2
]}

Hallek, Michael ^{[1
,2
]}

Cramer, Paula ^{[1
,2
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany

[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[4] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[5] Univ Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany

[6] Univ Rostock, Clin Hematol Oncol & Palliat Med 3, Rostock, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

CLL; second primary malignancies; obinutuzumab; ibrutinib; venetoclax; Phase; 2;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-465

引用

页码：S354 / S355

页数：2

共 50 条

[21] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
C-M Wendtner
M Ritgen
C D Schweighofer
G Fingerle-Rowson
H Campe
G Jäger
B Eichhorst
R Busch
H Diem
A Engert
S Stilgenbauer
H Döhner
M Kneba
B Emmerich
M Hallek
Leukemia, 2004, 18 : 1093 - 1101
[22] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
Wendtner, CM
Ritgen, M
Schweighofer, CD
Fingerle-Rowson, G
Campe, H
Jäger, G
Eichhorst, B
Busch, R
Diem, H
Engert, A
Stilgenbauer, S
Döhner, H
Kneba, M
Emmerich, B
Hallek, M
LEUKEMIA, 2004, 18 (06) : 1093 - 1101
[23] Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
Koeppler, Hubert
Fuss, Harald
Hurtz, Hans J.
Knigge, Owe
Losem, Christoph
Reschke, Daniel
Schmitz, Stephan
Weide, Rudolf
Weiss, Johann
Hallek, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 238 - 241
[24] Prognostic impact of common chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
Segura, Sonia Jaramillo
Agathangelidis, Andreas
Schneider, Christof
Bahlo, Jasmin
Robrecht, Sandra
Tausch, Eugen
Bloehdorn, Johannes
Hoechstetter, Manuela
Fischer, Kirsten
Eichhorst, Barbara
Goede, Valentin
Hallek, Michael
Doehner, Hartmut
Brandell, Richard Rosenquist
Ghia, Paolo
Stamatopoulos, Kostas
Stilgenbauer, Stephan
LEUKEMIA & LYMPHOMA, 2020, 61 : 135 - 136
[25] Fludarabine versus fludarabine plus cyclophosphamide as first line therapy of advanced chronic lymphocytic leukemia (CLL):: First interim analysis of a phase III study (CLL4 protocol) of the German CLL study group (GCLLSG).
Schmitt, BF
Bergmann, M
Busch, R
Wendtner, CM
Pasold, R
Anders, O
Sezer, O
Hurtz, HJ
Söling, U
Steinbrecher, C
Emmerich, B
Hallek, M
BLOOD, 2001, 98 (11) : 633A - 633A
[26] Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
Von Tresckow, Julia
Cramer, Paula
De Silva, Nisha
Bahlo, Jasmin
Robrecht, Sandra
Langerbeins, Petra
Fink, Anna-Maria
Al-Sawaf, Othman
Furstenau, Moritz
Illmer, Thomas
Klaproth, Holger
Tausch, Eugen
Ritgen, Matthias
Fischer, Kirsten
Wendtner, Clemens-Martin
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Boettcher, Sebastian
Eichhorst, Barbara F.
Hallek, Michael
BLOOD, 2019, 134
[27] INFLUENCE OF DIFFERENT TREATMENT REGIMENS ON SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - A META-ANALYSIS OF THE GERMAN CLL STUDY GROUP (GCLLSG)
Isfort, S.
Cramer, P.
Bahlo, J.
Busch, R.
Fischer, K.
Fink, A. M.
Goede, V.
Elter, T.
Bergmann, M.
Stauch, M.
Stilgenbauer, S.
Wendtner, C. M.
Hallek, M.
Eichhorst, B.
HAEMATOLOGICA, 2012, 97 : 56 - 56
[28] Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG)
Al-Sawaf, Othman
Robrecht, Sandra
Bahlo, Jasmin
Fink, Anna-Maria
Cramer, Paula
Maurer, Christian
Bergmann, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Jaeger, Ulrich
Wendtner, Clemens
Fischer, Kirsten
Goede, Valentin
Hallek, Michael
Eichhorst, Barbara
Hopfinger, Georg
Doehner, Hartmut
Kiehl, Michael
LEUKEMIA & LYMPHOMA, 2017, 58 : 62 - 63
[29] Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Results of the first interim ananlysis of a phase III study of the German CLL study group (GCLLSG).
Schmitt, BF
Franke, A
Burkhard, O
Schlag, R
Hopfinger, G
Stauch, M
Bergmann, M
Wendtner, CM
Busch, R
Emmerich, B
Hallek, N
BLOOD, 2002, 100 (11) : 364B - 364B
[30] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
Hallek, M
Wilhelm, M
Emmerich, B
Döhner, H
Fostitsch, HP
Sezer, O
Herold, M
Knauf, W
Busch, R
Schmitt, B
Wendtner, CM
Kuse, R
Freund, M
Franke, A
Schriever, F
Nerl, C
Thiel, E
Hiddemann, W
Brittinger, G
BLOOD, 1999, 94 (10) : 313A - 313A

← 1 2 3 4 5 →